×
About 137,060 results

Las vacunas contra el COVID-19: Efectos Secundarios - Dr. Castillo
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/428212

Se recomienda vacunar contra el COVID-19 a todas las personas que están embarazadas, en periodo de lactancia, que están intentando quedar embarazadas ahora o que podrían quedar embarazadas en el futuro. Vacunarse contra el COVID-19 durante el embarazo pue This video can also be viewed at https://www.cdc.gov/coronavirus/2019-ncov/videos/spanish/efectos-secundarios-drcastillo/testimony-kcastillo...

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer
https://www.onclive.com/view/agenus-withdraws-bla-for-balstilimab-in-metastatic-cervical-cancer

Oct 22nd, 2021 - The immuno-oncology company Agenus has made the decision to withdraw its biologic license application (BLA) for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.1 The decision follows the full approval of pembrolizumab (Keytruda) on October 13, 2021, for use as a single agent in pat...

Oncopeptides Withdraws Melphalan Flufenamide Myeloma Indication in the United States
https://www.onclive.com/view/oncopeptides-withdraws-melphalan-flufenamide-myeloma-indication-in-the-united-states

Oct 22nd, 2021 - Oncopeptides AB (publ) has made the decision to withdraw the indication of melphalan flufenamide (Pepaxto; melflufen) in combination with dexamethasone in select adult patients with relapsed or refractory multiple myeloma from the US market.1 In February 2021, the FDA approved melflufen plus dexamethasone for use in adult patients with relapsed/refractory multiple myeloma who have received at ...

Low androgen in kidney recipients tied to diabetes
https://www.mdedge.com/endocrinology/article/247792/diabetes/low-androgen-kidney-recipients-tied-diabetes
Miriam E. Tucker

Oct 22nd, 2021 - Low androgen levels appear to be linked to the development of posttransplantation diabetes mellitus (PTDM) in male kidney transplant recipients, new research suggests. London_England/Thinkstock Among 243 men who did not have diabetes prior to undergoing kidney transplantation, levels of both dihydrotestosterone (DHT) and testosterone were inversely related to the risk for developing diabetes th.

Exercise may help stall MS disability and progression
https://www.mdedge.com/neurology/article/247787/multiple-sclerosis/exercise-may-help-stall-ms-disability-and-progression
Jim Kling

Oct 22nd, 2021 - Though once regarded with suspicion, exercise as a therapy for multiple sclerosis (MS) has gained traction in recent years, and has the potential to counter the physical effects often seen among patients, as well as reduce risk of progression. Dr.

Explainer-Americans wonder: Which COVID-19 booster is best?
https://www.reuters.com/article/us-health-coronavirus-boosters-explainer/explainer-americans-wonder-which-covid-19-booster-is-best-idUSKBN2HC243

Oct 22nd, 2021 - CHICAGO (Reuters) - Americans this week were handed a big decision when it comes to getting a COVID-19 vaccine booster. The U.S. Centers for Disease Control and Prevention (CDC) on Thursday said individuals who qualify could choose a different vaccine from the one they received for their initial inoculation. For Americans asking how to choose, the following is what some experts advise: The CDC ...

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC
https://www.onclive.com/view/tas-102-plus-bevacizumab-misses-pfs-end-point-in-frontline-unresectable-metastatic-crc

Oct 22nd, 2021 - The frontline combination of trifluridine/tipiracil (TAS-102; Lonsurf) and bevacizumab (Avastin) was not found to result in a significant improvement in progression-free survival (PFS) over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer (mCRC) who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial (...

COVID Vaccine Recipients Also Less Likely to Die of Other Causes
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/95220

Oct 22nd, 2021 - People who were vaccinated against COVID-19 were also less likely to die from non-COVID-19-related causes compared with unvaccinated people, researchers found. The adjusted relative risk of non-COVID-19 mortality ranged from 0.31 (95% CI 0.30-0.33) for those who received two doses of Moderna to 0.54 (95% CI 0.49-0.59) for Johnson & Johnson recipients, reported Stanley Xu, PhD, of Kaiser Permane...

Will Slow and Steady Progress in Treating SCLC Win the Race?
https://www.onclive.com/view/will-slow-and-steady-progress-in-treating-sclc-win-the-race-

Oct 22nd, 2021 - Clinical advances in the treatment of small cell lung cancer (SCLC) have lagged behind those of other tumor types, but the delay is not for lack of effort. In recent years, however, improved understanding of disease biology has identified some novel targets that may make these tumors more vulnerable to treatment. One such approach in the frontline setting has been the integration of various imm...

Doctors urge unvaccinated Hungarians to avoid weekend rallies
https://www.reuters.com/article/us-health-coronavirus-hungary-healthcare/doctors-urge-unvaccinated-hungarians-to-avoid-weekend-rallies-idUSKBN2HC1DM

Oct 22nd, 2021 - BUDAPEST (Reuters) - Hungary’s main doctors’ association on Friday urged Hungarians not immunised against COVID-19 to stay away from mass rallies this weekend amid a rise in cases across central Europe. The region has the European Union’s lowest vaccination rates, an unwelcome distinction in which both political and economic factors play a role, and deadlier variants of the virus are spreading ...

Cabozantinib Shows Activity Against RCC Brain Metastases
https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/95201

Oct 22nd, 2021 - The tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) showed promising activity against brain metastases from renal cell carcinoma (RCC), researchers reported. In a retrospective cohort study of 88 patients with RCC brain metastases, the intracranial response rate with cabozantinib was 55% (95% CI 36-73%) in those with progressing brain metastases without concomitant brain-directed local...

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
https://www.onclive.com/view/ec-18-reduces-duration-and-incidence-of-chemoradiation-induced-oral-mucositis-in-head-and-neck-cancer

Oct 21st, 2021 - Treatment with the small molecule oral immunomodulator EC-18 resulted in a reduction in both the duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer who are undergoing concurrent chemoradiation, meeting both primary and secondary end points of the phase 2 CRIOM study (NCT03200340).1 With a short-term follow-up period, EC-18 reduced the duration of SOM fr...

Dr. McKinney on the Expanding Role of BTK Inhibitors in MCL
https://www.onclive.com/view/dr-mckinney-on-the-expanding-role-of-btk-inhibitors-in-mcl

Oct 21st, 2021 - Matthew S. McKinney, MD, cellular therapy specialist, hematologic oncologist, hematologist (malignant), Duke Health, discusses the expanding role of BTK inhibitors in mantle cell lymphoma (MCL). Several different BTK inhibitors are available for the treatment of patients with relapsed/refractory MCL, including ibrutinib (Imbruvica), which exhibited higher response rates compare with other trad...

Experts Answer Audience Questions Related to Adverse Events of BTKi
https://www.onclive.com/view/experts-answer-audience-questions-related-to-adverse-events-of-btki

Oct 21st, 2021 - Carrie Lenneman, MD, MSCI: In light of time, I’ll move to a couple of questions if you’re ready for that. Farrukh Awan, MD: Yes. Carrie Lenneman, MD, MSCI: The first one is, Have you seen low heart rate or bradycardia with ibrutinib? I can honestly say no, I have not seen that be a problem that wasn’t preidentified early. I don’t know what your experience is. Farrukh Awan, MD: I hav...

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
https://www.onclive.com/view/abid-on-optimizing-covid-19-vaccines-in-car-t-cell-therapy-recipients

Oct 21st, 2021 - Welcome to OncLive On Air®! I’m your host today, Kristi Rosa. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’s...

Is exercise therapy effective treatment for low back pain?
https://www.mdedge.com/familymedicine/article/247741/pain/exercise-therapy-effective-treatment-low-back-pain
MDedge Family Medicine; Christine Broszko, MD, FAAFP, Krystyna Golden, MD et. al.

Oct 21st, 2021 - EVIDENCE SUMMARY General exercise offers benefit …at least for chronic LBP A 2017 systematic review of 4 systematic reviews and 50 RCTs (122 total trials) evaluated general exercise vs usual care for acute (< 4 weeks), subacute (4 to 12 weeks), or chronic (≥ 12 weeks) LBP with or without radiculopathy in adults. 1 Exercise was not consistently associated with decreased pain in acute or subacute.

Oral Abx Cut Surgical Site Infections in Colorectal Surgeries
https://www.medpagetoday.com/surgery/generalsurgery/95181

Oct 21st, 2021 - Adding oral antibiotics to intravenous antibiotics with or without enema came out on top for reducing surgical site infections (SSIs) in patients undergoing elective colorectal surgeries, a network meta-analysis suggested. In the analysis of 35 randomized trials involving over 8,000 patients, this combination had the best probability of ranking first (86% chance) in reducing incisional SSIs, wh...

Dr. Thompson on the Safety Profile of Pirtobrutinib in Patients With Richter Transformation
https://www.onclive.com/view/dr-thompson-on-the-safety-profile-of-pirtobrutinib-in-patients-with-richter-transformation

Oct 20th, 2021 - Meghan Thompson, MD, third-year fellow, Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center, discusses the safety profile of pirtobrutinib (LOXO-305) in patients with Richter transformation. Findings from the phase 1/2 BRUIN study (NCT03740529) demonstrated a 67% overall response rate with pirtobrutinib, a noncovalent, oral BTK inhibitor, among 15 evaluable patients with...

Brigatinib Maintains Superior PFS Benefit Over Crizotinib With High Intracranial Efficacy in ALK+ NSCLC
https://www.onclive.com/view/brigatinib-maintains-superior-pfs-benefit-over-crizotinib-with-high-intracranial-efficacy-in-alk-nsclc

Oct 20th, 2021 - Brigatinib (Alunbrig) resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared with crizotinib (Xalkori) in patients with ALK-positive non–small cell lung cancer (NSCLC), according to final data from the phase 3 ALTA-1L trial (NCT02737501) presented during the 2021 ESMO Congress.1 At a median follow-up of 40....

No increased risk of relugolix side effects in fibroid, endometriosis patients
https://www.mdedge.com/obgyn/article/247665/gynecology/no-increased-risk-relugolix-side-effects-fibroid-endometriosis
Jaleesa Baulkman

Oct 20th, 2021 - Side effects from relugolix combination therapy (Myfembree) in premenopausal women treated for uterine fibroids and endometriosis are minimal, according to research presented at the American Society for Reproductive Medicine’s 2021 meeting. The Food and Drug Administration approved relugolix, a daily oral gonadotropin-releasing hormone antagonist medication, earlier this year to treat heavy men.